INTRODUCTION:
Acute myelogenous leukemia (AML) is the most common form of adult acute leukemia, ~12,000 cases being diagnosed annually in the United States 1 . For patients with high-risk or recurrent disease, hematopoietic cell transplantation (HCT) offers a potential cure [2] [3] . Successful allogeneic HCT depends upon elimination of leukemic cells by the combination of chemotherapy, radiotherapy and T-cell mediated graft-versus-leukemia reaction (GvL), with reconstitution of the patient's ablated hematopoietic system by donor stem cells. Although matching for HLA class I and II alleles is the most important criterion for unrelated donor selection, consideration of other factors, such as donor sex, parity, CMV serostatus and age can also improve transplant outcome [4] [5] [6] . Natural killer (NK) cells were discovered for their capacity to kill cancer cells 7 and only later shown to be an essential element of innate immunity Immunoglobulin-like Receptors (KIR) [11] [12] that recognize polymorphic epitopes of HLA-A, B and C, called KIR ligands 13 . As a consequence of this genetic variation, donor-derived NK cells can mediate beneficial GvL reactions in HCT. Such beneficial NK cell alloreactivity, which can be predicted from the differences in KIR-ligands between donor and recipient HLA class I type 14 , was first described for HLA haploidentical transplantation using an extensively T-cell depleted graft 15 and later investigated in other transplantation settings [16] [17] . These studies did not . This situation facilitated retrospective analysis to examine the impact of donor and recipient KIR genotypes on transplant outcome. The simplest genetic distinction is the division of KIR haplotypes into groups A and B according to gene content 12, 20 . KIR A haplotypes have simple, fixed gene content; B haplotypes have variable gene content and one or more of the Bspecific genes: KIR2DS1, 2, 3, 5, KIR2DL2, and 2DL5. Using this distinction, all individuals can be assigned to either the A/A genotype (homozygous for A haplotypes) or the B/x genotype (having one or two B haplotypes). Previously we showed that the outcome of unrelated donor transplantation for AML was significantly improved with B/x donors than A/A donors, whereas recipient KIR genotype had no effect 21 . Similar effects have been reported by others in unrelated donor and sibling donor settings [22] [23] . Because KIR B haplotypes are present in approximately 2/3 of unrelated registry donors, interventions that increase the probability of selecting KIR B donors are unlikely to impact survival since most donors already have this characteristic by chance. Further, the specific genetic mechanism for the protective effect of B haplotype donors, perhaps due to the presence or absence of individual or groups of inhibitory or activating KIR, remains unknown. This analysis was designed, from understanding of the organization of the KIR locus, to identify which particular B- Figure 1C) . A calculator for classification of the donor KIR B status (Best, Better, Neutral) can be found at www.ebi.ac.uk/ipd/kir/.
Statistical Analysis
Six measures of transplant outcome were considered: overall survival (OS) and disease-free survival (DFS), relapse, treatment-related mortality (TRM), and the incidence of both acute graft vs. host disease (GVHD) (grade II-IV) and chronic GVHD. OS and DFS were evaluated using Kaplan-Meier curves; other outcomes were evaluated using the cumulative incidence function. Unadjusted comparisons between KIR genotypes were made using the log rank test on either the hazard rates for OS and DFS or the crude hazard rates for relapse, TRM and chronic GVHD. For acute GVHD at 3 months we used the pseudoobservation approach 28 , which reduces to a logistic regression model when there is no censoring. In this transplant cohort the completeness of follow-up at 3 years was over 99% and 90% of the events had occurred. 
RESULTS:

Characteristics of the transplant recipients and donors studied
We studied 1409 myeloablative, T-cell replete URD transplants given to AML (n=1086) or ALL (n=323) patients, performed between 1988 and 2006 ( Table 1 Three conserved, framework regions divide the KIR locus into similarly sized centromeric and telomeric segments that differ in gene content 20, 27 . As shown in Figure 1A , the A haplotype has invariant gene-content, comprising a centromeric Table 2 ). However, the effect did not result in significantly increased DFS (Table 2b) Our study shows that the outcome of allogeneic transplantation for AML is influenced by the donor's KIR genotype in a manner that appears insensitive to the HLA type of either donor or recipient. Benefit accrues with increasing number of B haplotype genes, with the centromeric genes exerting a greater effect than the telomeric genes. These results imply that the success of transplantation for (Table 2) 
DISCUSSION:
For patients undergoing URD transplantation, the preferred donor is matched at the allele level for HLA class I and II [4] [5] . Even then, the risk of relapse is high (21 to 43% for early or advanced AML) and disease-free survival rates of 13-38% are the norm 30 . Here we investigated the contribution of a second immunogenetic system, the KIR gene family [34] [35] , the stronger avidity of KIR2DL2 than KIR2DL3 could educate NK cells that are more effective at eliminating residual AML cells.
The fact that Cen-B heterozygosity has a beneficial effect much less than half of that achieved by Cen-B homozygosity (Figure 2A, B) raises the possibility that a negative effect due to the KIR2DL3 component of Cen-A is the causative mechanism rather than a positive effect due to the KIR2DS2 and/or KIR2L2 of Cen-B/B. In the setting of acute hepatitis C virus infection, two copies of Cen-A were necessary to achieve a strong improvement in the response to infection 36 .
Here we find the opposite effect, namely that complete absence of Cen-A is required for strong improvement in the response to AML.
We should also consider the possibility that the clinical benefit associated with Cen-B/B homozygosity is not necessarily due to KIR2DS2, KIR2DL2 or KIR2DL3. The strong linkage disequilibrium between KIR2DS2 and KIR2DL2 12 extends into the 3' exons of the highly polymorphic framework gene, KIR3DL3 for which ligands and functions are unknown [37] [38] . Consequently, genetic analysis alone is unlikely to distinguish the contribution of individual Cen-B genes. Here, in contrast, we have focused on donor KIR gene variability, demonstrating a clinically significant influence on the success of transplantation for AML.
Previously we have shown that the use of donors with KIR B haplotypes, who express more activating KIR, was associated with significant improvements in overall and relapse-free survival after T cell replete, unrelated donor HCT for AML, with more than a 30% better relative risk in both these endpoints 21 . The benefit of donor KIR B haplotypes has also been observed for T-cell replete transplants from HLA matched sibling donors 47 , an effect reported in other settings [22] [23] . Numerous other studies have reported varied effects of activating KIR on outcomes after various types of HCT, including increased rates of acute 
